Retail Giants Turn GLP-1 Prescriptions Into Long-Term Customer Relationships as Employer Coverage Declines
核心洞察
Walmart, Costco, Amazon (搜索), and CVS are leveraging direct-to-consumer GLP-1 programs to capture patients losing employer-sponsored coverage for weight-loss drugs like Wegovy and Zepbound.
A Mercer survey shows 6% of large employers dropped GLP-1 coverage this year, with the drugs' share of claims swelling to 11.4% from 6.9% in 2023.
Retailers view GLP-1 prescriptions as a gateway to recurring customer relationships, with pharmacy visits driving grocery and merchandise sales across their networks.
As employer-sponsored coverage for GLP-1 weight-loss medications continues to erode, major retail pharmacy chains are racing to capture displaced patients through direct-to-consumer (DTC) prescription programs that promise affordability while building long-term customer relationships extending far beyond the pharmacy counter.
A Mercer survey released last month revealed that 6% of large employers dropped GLP-1 coverage this year, with the drugs' share of claims swelling to 11.4% from 6.9% in 2023. Health insurer Cigna announced earlier this month it would stop covering the medicines for its own employees, accelerating the shift toward DTC platforms.
"Every patient who loses coverage is choosing a new front door for care this year, and retailers are competing to be that door at the exact moment of the decision," said Jackie Swanson, managing partner at Gartner Consulting. "Real affordability gets delivered; a customer relationship gets acquired; both statements are true simultaneously."
The economics of pharmacy loyalty
Walmart, the nation's fifth-largest prescription provider with nearly 4,600 pharmacies, has moved aggressively to capture this shift. In April, the retailer expanded its Better Care Services digital platform to bundle GLP-1 prescriptions with weight-management support including nutrition coaching, fitness apps, and AI-driven coaching tools. According to Drug Channels Institute, Walmart currently holds 4.8% of the pharmacy market, trailing CVS's 14.7% and Walgreens' 14.6% — a gap the DTC GLP-1 strategy aims to narrow.
"Retailers are betting that if they can become the front door for obesity (搜索) care, they'll earn a relationship that extends far beyond a single GLP-1 prescription," said Eric Bormel, managing director specializing in digital healthcare at Solomon Partners' healthcare group.
The pricing structures themselves function as loyalty mechanisms. Eli Lilly's LillyDirect offers cash prices ranging from $299 to $449 per month, with better pricing tied to refilling within 45 days — "a loyalty program dressed as a discount schedule," Swanson noted. Novo Nordisk's NovoCare employs a $199 introductory price that later steps up to $349, which Swanson described as a "classic acquisition funnel." Costco's partnership with Sesame prices Wegovy at approximately $349 and requires a membership, meaning "the prescription now helps sell the $65 card," Swanson said.
Amazon (搜索) launched its own GLP-1 management program in April through Amazon One Medical and Amazon Pharmacy, offering insured patients prices as low as $25 per month with same-day delivery in nearly 3,000 cities, expanding to 4,500 by year's end.
Beyond the prescription: food and wellness
The GLP-1 phenomenon is reshaping grocery aisles as well. Costco CFO Gary Millerchip told investors during the retailer's third-quarter earnings call that "anything protein right now is doing extremely well," attributing the trend to GLP-1 drug influence. Popular new Kirkland private label items, including the Kirkland Signature Beef Stick and Kirkland Signature Ultra Filtered Protein Milk, have seen surging demand.
Publix announced a free "Create a lifestyle that lasts" brochure designed to guide weight-loss drug users toward protein and fiber options, complemented by "Better Choice" shelf tags identifying items that registered dietitian nutritionists have determined contain vital nutrients. Meijer has launched over 120 store-brand products with at least 5 grams of fiber per serving, calling increased fiber intake "the breakout nutrition goal for 2026."
Independent pharmacies and safety concerns
The DTC shift presents significant challenges for independent pharmacies. Seth Friedman, pharmacy and health plan services practice leader at Gallagher, said smaller pharmacies "stand to lose volume for sure."
Dared Price, who owns nine pharmacies in small Kansas towns, described the frustration of watching customers migrate to large chains. "It puts independent pharmacies at a big disadvantage," Price said. More critically, he raised safety concerns: "My system won't flag any drug interactions with GLP drugs and there are drug interactions that can be dangerous," citing known interactions with insulin and oral contraceptives.
CVS defended its approach. "Access is only part of the equation with GLP-1 medications. Patients also need support to stay on therapy and see results," said Sid Tenneti, senior vice president and interim president, pharmacy and consumer wellness.
A new Centers for Medicare & Medicaid Services initiative launched July 1 offers eligible Medicare patients GLP-1s for weight loss at a flat $50 monthly copay, though it runs through a single central processor rather than a patient's regular pharmacy — a structural gap that concerns some obesity (搜索)-care specialists.
"In a retail industry that spends billions chasing foot traffic, that is the most reliable recurring customer relationship on the market," Swanson said. "The retailer that fills the prescription tends to sell the groceries too, and pharmacy is quietly becoming the membership battleground of American retail."